NO323994B1 - Fremgangsmate for affinitetsseparasjon, samt albuminbindingsprotein, fusjonsprotein, nukleinsyremolekyl og vertscelle. - Google Patents
Fremgangsmate for affinitetsseparasjon, samt albuminbindingsprotein, fusjonsprotein, nukleinsyremolekyl og vertscelle. Download PDFInfo
- Publication number
- NO323994B1 NO323994B1 NO20011969A NO20011969A NO323994B1 NO 323994 B1 NO323994 B1 NO 323994B1 NO 20011969 A NO20011969 A NO 20011969A NO 20011969 A NO20011969 A NO 20011969A NO 323994 B1 NO323994 B1 NO 323994B1
- Authority
- NO
- Norway
- Prior art keywords
- protein
- affinity
- ligand
- fragment
- derivative
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 45
- 238000000926 separation method Methods 0.000 title claims abstract description 26
- 102000037865 fusion proteins Human genes 0.000 title claims description 11
- 108020001507 fusion proteins Proteins 0.000 title claims description 11
- 102000039446 nucleic acids Human genes 0.000 title claims description 10
- 108020004707 nucleic acids Proteins 0.000 title claims description 10
- 150000007523 nucleic acids Chemical class 0.000 title claims description 10
- 102000009027 Albumins Human genes 0.000 title claims description 9
- 108010088751 Albumins Proteins 0.000 title claims description 9
- 108091008324 binding proteins Proteins 0.000 title claims description 8
- 102000014914 Carrier Proteins Human genes 0.000 title description 4
- 230000008569 process Effects 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 123
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 114
- 235000018102 proteins Nutrition 0.000 claims abstract description 111
- 239000003446 ligand Substances 0.000 claims abstract description 51
- 238000009739 binding Methods 0.000 claims abstract description 48
- 230000027455 binding Effects 0.000 claims abstract description 47
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims abstract description 12
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000009582 asparagine Nutrition 0.000 claims abstract description 7
- 229960001230 asparagine Drugs 0.000 claims abstract description 7
- 235000001014 amino acid Nutrition 0.000 claims description 38
- 229940024606 amino acid Drugs 0.000 claims description 36
- 150000001413 amino acids Chemical class 0.000 claims description 36
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 29
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 26
- 230000000717 retained effect Effects 0.000 claims description 9
- 108010088160 Staphylococcal Protein A Proteins 0.000 claims description 7
- 102000052510 DNA-Binding Proteins Human genes 0.000 claims description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- 101710096438 DNA-binding protein Proteins 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- 102000023732 binding proteins Human genes 0.000 claims 4
- 230000004048 modification Effects 0.000 abstract description 5
- 238000012986 modification Methods 0.000 abstract description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 51
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 22
- 238000006467 substitution reaction Methods 0.000 description 16
- 238000000746 purification Methods 0.000 description 15
- 239000003513 alkali Substances 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 238000002703 mutagenesis Methods 0.000 description 12
- 231100000350 mutagenesis Toxicity 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 239000012491 analyte Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 238000001042 affinity chromatography Methods 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 230000009870 specific binding Effects 0.000 description 9
- 235000004279 alanine Nutrition 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 229920002684 Sepharose Polymers 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 230000006240 deamidation Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 238000011105 stabilization Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108010058683 Immobilized Proteins Proteins 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002708 random mutagenesis Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 241000724791 Filamentous phage Species 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- -1 cyclic imide Chemical class 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001641 gel filtration chromatography Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- KLKHFFMNGWULBN-VKHMYHEASA-N Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)NCC(O)=O KLKHFFMNGWULBN-VKHMYHEASA-N 0.000 description 1
- SONUFGRSSMFHFN-IMJSIDKUSA-N Asn-Ser Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O SONUFGRSSMFHFN-IMJSIDKUSA-N 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000194015 Streptococcus sp. G148 Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 125000003164 beta-aspartyl group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9823071.7A GB9823071D0 (en) | 1998-10-21 | 1998-10-21 | A method |
| PCT/GB1999/003484 WO2000023580A1 (en) | 1998-10-21 | 1999-10-21 | A method of affinity separation and ligands for use therein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20011969D0 NO20011969D0 (no) | 2001-04-20 |
| NO20011969L NO20011969L (no) | 2001-06-19 |
| NO323994B1 true NO323994B1 (no) | 2007-07-30 |
Family
ID=10841043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20011969A NO323994B1 (no) | 1998-10-21 | 2001-04-20 | Fremgangsmate for affinitetsseparasjon, samt albuminbindingsprotein, fusjonsprotein, nukleinsyremolekyl og vertscelle. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6831161B1 (de) |
| EP (2) | EP1123389B1 (de) |
| JP (1) | JP4801258B2 (de) |
| AT (1) | ATE305970T1 (de) |
| AU (1) | AU773368B2 (de) |
| CA (2) | CA2347960C (de) |
| DE (1) | DE69927598T2 (de) |
| DK (1) | DK1123389T3 (de) |
| GB (1) | GB9823071D0 (de) |
| NO (1) | NO323994B1 (de) |
| WO (1) | WO2000023580A1 (de) |
| ZA (1) | ZA200103252B (de) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7709209B2 (en) | 2002-03-25 | 2010-05-04 | Ge Healthcare Bio-Sciences Ab | Protein ligands |
| SE0200943D0 (sv) * | 2002-03-25 | 2002-03-25 | Amersham Biosciences Ab | Mutant protein |
| GB0214007D0 (en) * | 2002-06-18 | 2002-07-31 | Common Services Agency | Removal of prion infectivity |
| EP1634076A2 (de) * | 2003-06-10 | 2006-03-15 | CatchMabs B.V. | Bindungs peptide: methoden zur herstellung und verwendung |
| SE0301936D0 (sv) * | 2003-06-30 | 2003-06-30 | Affibody Ab | New polypeptide |
| ATE416190T1 (de) | 2003-07-04 | 2008-12-15 | Affibody Ab | Polypeptide mit bindungsaffinität für her2 |
| DE05733048T1 (de) | 2004-04-06 | 2007-05-10 | Affibody Ab | Serumalbuminbindende peptidkonjugate zur arzneimittelherstellung |
| CN106422418B (zh) | 2006-09-29 | 2022-03-01 | 思拓凡生物工艺研发有限公司 | 用于抗体分离的包含来自金黄色葡萄球菌a蛋白的结构域c的层析配体 |
| EP2546261A3 (de) * | 2007-07-31 | 2013-08-14 | Affibody AB | Neue Zusammensetzungen, Verfahren und Verwendung |
| GB2452301A (en) * | 2007-08-30 | 2009-03-04 | Ge Healthcare Bio Sciences Ab | Sterilization Method |
| US8592555B2 (en) * | 2008-08-11 | 2013-11-26 | Emd Millipore Corporation | Immunoglobulin-binding proteins with improved specificity |
| EP2339339A4 (de) * | 2008-09-25 | 2016-10-12 | Jsr Corp | Füllmittel für affinitätschromatographie |
| JP5229888B2 (ja) * | 2008-09-30 | 2013-07-03 | 独立行政法人産業技術総合研究所 | 弱酸性域での易解離性を向上したプロテインａ変異型タンパク質及び抗体捕捉剤 |
| SG195555A1 (en) | 2008-12-24 | 2013-12-30 | Emd Millipore Corp | Caustic stable chromatography ligands |
| EP2412809B1 (de) | 2009-03-24 | 2017-08-09 | Kaneka Corporation | Protein mit immunglobulinaffinität und ligand mit affinität für immunglobulinbindung |
| CN102844432A (zh) | 2010-03-24 | 2012-12-26 | 株式会社钟化 | 特异性结合免疫球蛋白的蛋白质以及免疫球蛋白结合性亲和配体 |
| KR101461772B1 (ko) | 2010-12-21 | 2014-12-03 | 제이에스알 가부시끼가이샤 | 친화성 크로마토그래피용 담체 및 면역 글로불린을 단리하는 방법 |
| US9051375B2 (en) | 2010-12-21 | 2015-06-09 | The University Of Western Ontario | Alkali-resistant variants of protein A and their use in affinity chromatography |
| JP6038774B2 (ja) | 2011-03-24 | 2016-12-07 | 株式会社カネカ | タンパク性物質結合性低分子化合物 |
| JP5933526B2 (ja) | 2011-03-25 | 2016-06-08 | 株式会社カネカ | 免疫グロブリン結合性新規ポリペプチド |
| SG10201604559TA (en) | 2011-06-08 | 2016-07-28 | Emd Millipore Corp | Chromatography matrices including novel staphylococcus aureus protein a based ligands |
| WO2014076179A1 (en) | 2012-11-14 | 2014-05-22 | Affibody Ab | New polypeptide |
| WO2014076177A1 (en) * | 2012-11-14 | 2014-05-22 | Affibody Ab | New polypeptide |
| US9255262B2 (en) * | 2013-03-06 | 2016-02-09 | Vision Global Holdings Ltd. | Albumin-binding arginine deminase and the use thereof |
| USRE48805E1 (en) | 2013-03-06 | 2021-11-02 | Vision Global Holdings Ltd. | Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein |
| EP3041857B1 (de) | 2013-09-04 | 2019-05-08 | EMD Millipore Corporation | Protein a chromatographie |
| JP6491600B2 (ja) | 2013-09-27 | 2019-03-27 | 株式会社カネカ | アルカリ水溶液を用いた多孔質セルロースビーズの製造方法 |
| CN110054661A (zh) | 2013-12-12 | 2019-07-26 | Emd密理博公司 | 使用含丙烯酰胺的过滤器分离蛋白 |
| JP6369807B2 (ja) * | 2014-10-21 | 2018-08-08 | 株式会社プロテイン・エクスプレス | プロテインｌ変異体 |
| WO2016121701A1 (ja) | 2015-01-26 | 2016-08-04 | 株式会社カネカ | 免疫グロブリンκ鎖可変領域含有タンパク質精製用アフィニティー分離マトリックス |
| JP6663360B2 (ja) | 2015-01-26 | 2020-03-11 | 株式会社カネカ | 変異型免疫グロブリンκ鎖可変領域結合性ペプチド |
| CN107429244A (zh) | 2015-03-26 | 2017-12-01 | Jsr株式会社 | 免疫球蛋白结合蛋白质和使用其的亲和载体 |
| WO2016168771A2 (en) | 2015-04-17 | 2016-10-20 | Alpine Immune Sciences, Inc. | Immunomodulatory proteins with tunable affinities |
| US11208441B2 (en) | 2015-10-22 | 2021-12-28 | Protenova Co., Ltd. | Immunoglobulin-binding polypeptide |
| WO2017191748A1 (ja) * | 2016-05-02 | 2017-11-09 | 株式会社カネカ | 改変型免疫グロブリンκ鎖可変領域結合性ペプチド |
| WO2017195638A1 (ja) | 2016-05-09 | 2017-11-16 | 株式会社カネカ | 抗体またはκ鎖可変領域含有抗体断片の精製方法 |
| EP3592759A1 (de) | 2017-03-07 | 2020-01-15 | JMVA Biotech AB | Modifizierte adsorptive oberflächen |
| JP7159175B2 (ja) | 2017-09-25 | 2022-10-24 | Jsr株式会社 | イムノグロブリン結合タンパク質、及びそれを用いたアフィニティー担体 |
| JP7335881B2 (ja) | 2018-08-24 | 2023-08-30 | Jsr株式会社 | イムノグロブリン結合タンパク質、及びそれを用いたアフィニティー担体 |
| US20240026344A1 (en) | 2020-10-13 | 2024-01-25 | Avitide LLC | Affinity ligand libraries of three-helix bundle proteins and uses thereof |
| US20240043478A1 (en) | 2020-12-22 | 2024-02-08 | Protenova Co., Ltd. | Immunoglobulin-binding polypeptide |
| KR20240000462A (ko) | 2021-02-19 | 2024-01-02 | 아비타이드 엘엘씨 | Aav2 친화성 제제 |
| GB2609185A (en) | 2021-05-24 | 2023-02-01 | Astrea Uk Services Ltd | Scaffold for isolation of a biomolecule |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE462046C (sv) * | 1982-08-23 | 1998-04-27 | Pharmacia Biotech Ab | Hybrid-DNA-vektor innehållande DNA-sekvens från Staphylococcus aureus, förfarande för dess framställning och bakterie innehållande densamma |
| US5401832A (en) * | 1984-12-24 | 1995-03-28 | Merck & Co., Inc. | Brain derived and recombinant acidic fibroblast growth factor |
| US5089473A (en) * | 1988-08-29 | 1992-02-18 | Monsanto Company | Somatotropin variants and their use |
| JP2584697B2 (ja) * | 1991-08-23 | 1997-02-26 | オリエンタル酵母工業株式会社 | ＩｇＧ精製用組換え型プロテインＡ |
| DE69230061T2 (de) * | 1991-07-25 | 2000-01-05 | Oriental Yeast Co. Ltd., Tokio/Tokyo | Künstliches immunoglobulin-bindendes protein |
| DE59306762D1 (de) * | 1992-04-16 | 1997-07-24 | Merck Patent Gmbh | Aktivierte Trägermaterialien, ihre Herstellung und Verwendung |
| SE9400088D0 (sv) * | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| US5736499A (en) * | 1995-06-06 | 1998-04-07 | Genencor International, Inc. | Mutant A-amylase |
| SE9503925D0 (sv) * | 1995-11-07 | 1995-11-07 | Pharmacia Biotech Ab | Separationsmedium för IgG |
| WO1998040488A1 (en) * | 1997-03-12 | 1998-09-17 | Smithkline Beecham Corporation | Anti-alphabeta3 humanized monoclonal antibodies |
-
1998
- 1998-10-21 GB GBGB9823071.7A patent/GB9823071D0/en not_active Ceased
-
1999
- 1999-10-21 EP EP99950942A patent/EP1123389B1/de not_active Expired - Lifetime
- 1999-10-21 WO PCT/GB1999/003484 patent/WO2000023580A1/en active IP Right Grant
- 1999-10-21 DE DE69927598T patent/DE69927598T2/de not_active Expired - Lifetime
- 1999-10-21 CA CA002347960A patent/CA2347960C/en not_active Expired - Lifetime
- 1999-10-21 EP EP05077192A patent/EP1672068A1/de not_active Ceased
- 1999-10-21 JP JP2000577291A patent/JP4801258B2/ja not_active Expired - Lifetime
- 1999-10-21 AT AT99950942T patent/ATE305970T1/de not_active IP Right Cessation
- 1999-10-21 CA CA2633345A patent/CA2633345C/en not_active Expired - Lifetime
- 1999-10-21 AU AU63532/99A patent/AU773368B2/en not_active Expired
- 1999-10-21 DK DK99950942T patent/DK1123389T3/da active
- 1999-10-21 US US09/830,080 patent/US6831161B1/en not_active Expired - Lifetime
-
2001
- 2001-04-20 ZA ZA200103252A patent/ZA200103252B/en unknown
- 2001-04-20 NO NO20011969A patent/NO323994B1/no not_active IP Right Cessation
-
2004
- 2004-12-01 US US11/000,747 patent/US20050100970A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1672068A1 (de) | 2006-06-21 |
| EP1123389A1 (de) | 2001-08-16 |
| US20050100970A1 (en) | 2005-05-12 |
| AU6353299A (en) | 2000-05-08 |
| JP2002527107A (ja) | 2002-08-27 |
| ATE305970T1 (de) | 2005-10-15 |
| WO2000023580A1 (en) | 2000-04-27 |
| CA2633345A1 (en) | 2000-04-27 |
| DK1123389T3 (da) | 2006-01-16 |
| JP4801258B2 (ja) | 2011-10-26 |
| CA2347960C (en) | 2008-08-05 |
| CA2633345C (en) | 2013-02-26 |
| DE69927598T2 (de) | 2006-07-13 |
| AU773368B2 (en) | 2004-05-20 |
| EP1123389B1 (de) | 2005-10-05 |
| GB9823071D0 (en) | 1998-12-16 |
| ZA200103252B (en) | 2002-07-22 |
| NO20011969L (no) | 2001-06-19 |
| DE69927598D1 (de) | 2006-02-16 |
| CA2347960A1 (en) | 2000-04-27 |
| NO20011969D0 (no) | 2001-04-20 |
| US6831161B1 (en) | 2004-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO323994B1 (no) | Fremgangsmate for affinitetsseparasjon, samt albuminbindingsprotein, fusjonsprotein, nukleinsyremolekyl og vertscelle. | |
| KR102573370B1 (ko) | 신규한 알칼리 안정성 면역글로불린 결합 단백질 | |
| KR102064396B1 (ko) | 신규한 면역글로불린-결합 단백질 및 친화도 정제에서의 이의 용도 | |
| EP1992692B1 (de) | Immunglobulin-affinitätsligand | |
| EP3521304B1 (de) | Fc-bindungsproteine mit cystein in der c-terminalen helikalen region | |
| JP5951509B2 (ja) | 免疫グロブリンＧＦｃ領域結合ポリペプチド | |
| CN111132994B (zh) | 在c末端螺旋区中具有半胱氨酸的fc结合蛋白 | |
| KR20110003547A (ko) | 인위적인 단백질 스캐폴드 | |
| EP3546476A1 (de) | Fc-bindungsproteine mit cystein in der c-terminalen helikalen region |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |